Bicycle Therapeutics rises as cancer drug study shows positive response

Bicycle Therapeutics

14/02/2023 15:23

** Shares of drug developer Bicycle Therapeutics Plc
 BCYC.O  rise 7.3% to $27.94 
    ** Co says experimental drug BT8009 demonstrates anti-tumor
activity in heavily pre-treated urothelial, lung and breast
cancer patients, by targeting a tumor-promoting antigen called
Nectin-4
    ** BT8009 was well tolerated across all 49 patients in the
ongoing early-to-mid stage study - BCYC
    ** Says 50% overall response rate and 75% clinical benefit
rate noted in 24 urothelial cancer patients
    ** Co notes, as of Jan 2023, median duration of response
estimated to be about 14 months among urothelial cancer patients
    ** Announces confirmed partial responses in non-small cell
lung cancer (NSCLC) and breast cancer patients
    ** A mid-stage combination study of BT8009, with
pembrolizumab immunotherapy, remains on track to commence this
year - BCYC
    ** Stock fell 45% in last 12 months
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))